Download, Immune Response and Therapies

Drug repurposing in SARS-CoV-2 / COVID-19: preventing the maladaptive immune response leading to critical disease requiring ICU care.

Plenge Gen

APRIL 7, 2020

You can download a pdf copy of the blog here.) Repurposing of approved therapies is the fastest way to impact patients today, as these medicines have regulatory approval to enable investigator-initiated trials and have a manufacturing process to ensure drug supply. The views expressed here are my own.]

Immune Response

Immune Response Disease Clinical Trials Drugs

Apexigen’s APX005M Granted Orphan Drug Designations for the Treatment of Esophageal and Gastroesophageal Junction Cancer and for the Treatment of Pancreatic Cancer

The Pharma Data

OCTOBER 14, 2020

APX005M is a novel, humanized monoclonal antibody that stimulates the anti-tumor immune response. APX005M targets CD40, a co-stimulatory receptor that is essential for activating both innate and adaptive immune systems. View original content to download multimedia: [link]. About Apexigen. SOURCE Apexigen, Inc.

Treatment

Treatment Immune Response Clinical Trials Clinical Development

ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology

The Pharma Data

JANUARY 6, 2021

Quantitative imaging of CD8 T cells enables quicker identification of drug efficacy, therefore potentially reducing the length of clinical trials, reducing costs and helping new therapies to advance to market faster, which ultimately will improve treatment and care of cancer patients. View original content to download multimedia: [link].

Licensing

Licensing Licensing Clinical Trials Pharmaceutical Companies

Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet

The Pharma Data

JANUARY 31, 2021

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. View original content to download multimedia: [link]. CHENGDU, China , Feb. About Dynavax. SOURCE Clover Biopharmaceuticals. Source link.

Clinical Trials

Clinical Trials Vaccine Trials Virus

Scaling Phage Therapy

Codon

FEBRUARY 13, 2024

Tom Ireland writes about the companies and technologies that are reimagining phage therapy. Soon after its publication, scientists, journalists, and investors were revisiting ‘phage therapy’ as a promising alternative to our failing antibiotics. Read it on our website here. Illustration by David S. Fast forward to 2023.

Therapies

Therapies DNA Virus Clinical Trials

Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate

The Pharma Data

JANUARY 31, 2021

Clover’s S-Trimer antigen adjuvanted with CpG 1018 plus alum demonstrated low reactogenicity while providing high levels of neutralizing antibodies and a strong Th1-biased cell-mediated immune response. Dynavax developed CpG 1018 to provide an increased vaccine immune response, which has been demonstrated in HEPLISAV-B.

Vaccine

Vaccine Trials Virus RNA

Moleculin Announces Annamycin Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas

The Pharma Data

DECEMBER 28, 2020

. Moleculin recently announced that the FDA had allowed its request for Investigational New Drug (IND) status for Annamycin, allowing Moleculin to begin a Phase 1B /2 clinical trial in the US for patients with soft tissue sarcoma (STS) that has metastasized to the lungs after first-line therapy for their disease.

FDA

FDA Clinical Trials Drugs Pharmaceutical Companies

Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock – Oct 28, 2020

The Pharma Data

OCTOBER 27, 2020

Sitravatinib is an investigational spectrum-selective inhibitor of receptor tyrosine kinases (RTK) designed to enhance immune responses through the inhibition of immunosuppressive signaling. View original content to download multimedia: [link]. SOURCE Mirati Therapeutics, Inc. Company Codes: NASDAQ-SMALL:MRTX.

Small Molecule

Small Molecule Immune Response Clinical Development Clinical Trials

Moleculin Announces Independent Study Validates Annamycin’s Ability to Target Lung Localized Tumors

The Pharma Data

OCTOBER 20, 2020

” The relevance of targeting lung localized tumors is that it could provide a means to address a significant unmet need in cancer therapy. View original content to download multimedia: [link]. We are hopeful we can submit this IND before year-end.” Forward-Looking Statements.

Clinical Trials

Clinical Trials Pharmaceutical Companies Treatment Immune Response

Codon Digest: Vaccine Printer Go Brrrrr!

Codon

APRIL 30, 2023

In one experiment, the microneedle patches were used to deliver a SARS-CoV-2 vaccine into mice, producing immune responses similar to a traditional injection. Printed vaccines caused mice to have a faster immune response. difficile therapy. But the printed vaccines are very good! vander Straeten et al.

Vaccine

Vaccine DNA Engineering RNA

Codon Digest: Vaccine Printer Go Brrrrr!

Codon

APRIL 30, 2023

In one experiment, the microneedle patches were used to deliver a SARS-CoV-2 vaccine into mice, producing immune responses similar to a traditional injection. Printed vaccines caused mice to have a faster immune response. difficile therapy. But the printed vaccines are very good! vander Straeten et al.

Vaccine

Vaccine DNA Engineering RNA

Cytiva supports Clover Biopharmaceuticals to scale up the output of its vaccine candidate

The Pharma Data

NOVEMBER 15, 2020

As the first company in the world to produce a COVID-19 vaccine candidate that is successfully recognized by antibodies produced by previously-infected patients, Clover demonstrates that S-Trimer has preserved the native structure of the viral spike (S) protein and thus may elicit a protective-immune response as a vaccine.

Vaccine

Vaccine Immune Response Clinical Trials Science

Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma

The Pharma Data

DECEMBER 21, 2020

In September 2018 , the US Food and Drug Administration granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma, without an eosinophilic phenotype. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses and other airborne particles.

Trials

Trials Production Clinical Trials Therapies

Tezepelumab NAVIGATOR Phase 3 Trial Met Primary Endpoint Of A Statistically Significant And Clinically Meaningful Reduction In Exacerbations In A Broad Population Of Patients With Severe Asthma

The Pharma Data

NOVEMBER 9, 2020

Food and Drug Administration Breakthrough Therapy Designation granted to tezepelumab in Sept. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses and other airborne particles. It’s a commitment that extends beyond introducing novel therapies.

Trials

Trials Production Clinical Trials Government

BioInvent and Transgene receive CTA approval for Phase l/lla trial of oncolytic virus BT-001 in solid tumors

The Pharma Data

DECEMBER 20, 2020

This oncolytic virus has induced long-lasting antitumor immune responses and abscopal effects in several tumor models, and its activity is further enhanced through combination with an anti-PD-1 antibody treatment. The following files are available for download: View original content: [link]. About BioInvent. SOURCE BioInvent.

Virus

Virus Trials Clinical Trials Clinical Development

Transgene Announces Detailed Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-positive Cancers

The Pharma Data

OCTOBER 26, 2020

Following the unauthorized download of all abstracts on the SITC website, Transgene is communicating the content of the late-breaking poster abstract that will be presented at the SITC 35th Anniversary Annual Meeting (SITC 2020), to be held virtually November 9-14, 2020. . An overall response rate of 23.5%

Vaccine

Vaccine Trials Treatment Virus

Dynavax Announces Final Immunogenicity and Interim Safety Results from Clinical Trial Evaluating HEPLISAV-B in Patients Undergoing Hemodialysis

The Pharma Data

JANUARY 6, 2021

. About HEPLISAV-B HEPLISAV-B is an adult hepatitis B vaccine that combines hepatitis B surface antigen with Dynavax’s proprietary Toll-like Receptor (TLR) 9 agonist adjuvant CpG 1018 to enhance the immune response. View original content to download multimedia: [link]. ii CDC.

Clinical Trials

Clinical Trials Trials Vaccine Immune Response

Drug Discovery Digest

Drug repurposing in SARS-CoV-2 / COVID-19: preventing the maladaptive immune response leading to critical disease requiring ICU care.

Apexigen’s APX005M Granted Orphan Drug Designations for the Treatment of Esophageal and Gastroesophageal Junction Cancer and for the Treatment of Pancreatic Cancer

Trending Sources

ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology

Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet

Scaling Phage Therapy

Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate

Moleculin Announces Annamycin Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas

Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock – Oct 28, 2020

Moleculin Announces Independent Study Validates Annamycin’s Ability to Target Lung Localized Tumors

Codon Digest: Vaccine Printer Go Brrrrr!

Codon Digest: Vaccine Printer Go Brrrrr!

Cytiva supports Clover Biopharmaceuticals to scale up the output of its vaccine candidate

Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma

Tezepelumab NAVIGATOR Phase 3 Trial Met Primary Endpoint Of A Statistically Significant And Clinically Meaningful Reduction In Exacerbations In A Broad Population Of Patients With Severe Asthma

BioInvent and Transgene receive CTA approval for Phase l/lla trial of oncolytic virus BT-001 in solid tumors

Transgene Announces Detailed Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-positive Cancers

Dynavax Announces Final Immunogenicity and Interim Safety Results from Clinical Trial Evaluating HEPLISAV-B in Patients Undergoing Hemodialysis

Stay Connected